We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanodiamonds Dramatically Boost Immunoassay Sensitivity

By LabMedica International staff writers
Posted on 08 Dec 2020
Incorporation of a specific class of nanodiamond into lateral flow immunoassays was shown to increase the sensitivity of this method by at least five orders of magnitude.

Nanodiamonds or diamond nanoparticles are diamonds with a size below one micrometer, which are commercially produced by detonation synthesis. More...
A class of fluorescent nanodiamonds containing nitrogen-vacancy defects has attractive properties for in vitro biosensing, including brightness, low cost, and selective manipulation of their emission.

Investigators at University College London (United Kingdom) studied fluorescent nanodiamonds as an ultrasensitive label for in vitro diagnostics, using a microwave field to modulate emission intensity and frequency-domain analysis to separate the signal from background autofluorescence, which typically limits sensitivity. Since the quantum properties of fluorescent nanodiamonds allow their emission to be selectively modulated, the signal can be fixed at a set frequency using a microwave field and can be efficiently separated from the background fluorescence.

Using lateral flow immunoassay as the experimental system, the investigators achieved a detection limit of 8.2 × 10−19 molar for a biotin–avidin model, 100,000 times more sensitive than that obtained using gold nanoparticles. Furthermore, single-copy detection of HIV-1 RNA could be achieved with the addition of a 10-minute isothermal recombinase polymerase amplification step. This method was then demonstrated using a clinical plasma sample with an extraction step.

Senior author Dr. Rachel McKendry, professor of biomedical nanotechnology at University College London, said, "Our proof-of-concept study shows how quantum technologies can be used to detect ultralow levels of virus in a patient sample, enabling much earlier diagnosis. We have focused on the detection of HIV, but our approach is very flexible and can be easily adapted to other diseases and biomarker types. We are working on adapting our approach to COVID-19. We believe that this transformative new technology will benefit patients and protect populations from infectious diseases."

The next step will be to adapt the assay for use a smartphone or portable fluorescence reader, which would allow the test to be performed in low-resource settings.

The use of nanodiamonds to increase the sensitivity of lateral flow assays was described in the November 25, 2020, online edition of the journal Nature.

Related Links:
University College London


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.